Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,075.00

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective raised by Barclays from $917.00 to $1,075.00 in a report published on Tuesday,Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. Truist Financial upped their price target on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Cantor Fitzgerald lifted their price objective on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. Finally, JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $904.41.

Check Out Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $923.34 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89. The company has a 50 day moving average price of $826.97 and a 200 day moving average price of $751.27. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The stock has a market capitalization of $95.52 billion, a PE ratio of 19.80, a price-to-earnings-growth ratio of 1.25 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period last year, the company earned $11.83 EPS. Analysts forecast that Regeneron Pharmaceuticals will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Joseph Larosa sold 4,466 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the sale, the executive vice president owned 38,906 shares in the company, valued at approximately $37,563,353.94. The trade was a 10.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at $542,700. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 32,039 shares of company stock worth $29,825,285. Corporate insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $5,682,636,000. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 1.0% in the 3rd quarter. State Street Corp now owns 4,881,362 shares of the biopharmaceutical company’s stock valued at $3,701,390,000 after acquiring an additional 46,674 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Regeneron Pharmaceuticals by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock valued at $805,023,000 after acquiring an additional 101,469 shares during the last quarter. Amundi increased its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock valued at $631,983,000 after acquiring an additional 3,742 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in shares of Regeneron Pharmaceuticals by 51.1% in the 3rd quarter. First Trust Advisors LP now owns 826,770 shares of the biopharmaceutical company’s stock valued at $626,915,000 after acquiring an additional 279,638 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Investors following REGN have been watching these headlines:

  • Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with anti-AChR-positive generalized myasthenia gravis. It is the first approved siRNA therapy for the disease and the only treatment described as requiring just four subcutaneous doses per year. Approval was based on Phase 3 results showing sustained disease control. Livsayis is Regeneron’s first marketed RNAi drug and its first neurology medicine. Reuters article
  • Positive Sentiment: Regeneron plans to present new and updated data from its blood-disorder pipeline at the December ASH meeting, including potentially pivotal Ordspono data in marginal zone lymphoma and Lynozyfic data in AL amyloidosis. These updates may offer future growth opportunities, though they are not yet clinical or regulatory outcomes. ASH pipeline update
  • Negative Sentiment: Livsayis will enter a market with established treatments from AstraZeneca and Argenx, so commercial uptake and competition will influence how much the approval adds to Regeneron’s results. Market competition article

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Recommended Stories

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.